Battarbee Ashley N, Mele Lisa, Landon Mark B, Varner Michael W, Casey Brian M, Reddy Uma M, Wapner Ronald J, Rouse Dwight J, Thorp John M, Chien Edward K, Saade George, Peaceman Alan M, Blackwell Sean C
Departments of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
George Washington University Biostatistics Center, Washington, District of Columbia.
Am J Perinatol. 2024 May;41(S 01):e1976-e1981. doi: 10.1055/a-2096-0443. Epub 2023 May 18.
This study aimed to measure the association between hypertensive disorders of pregnancy (HDP) and long-term maternal metabolic and cardiovascular biomarkers.
Follow-up study of patients who completed glucose tolerance testing 5 to 10 years after enrollment in a mild gestational diabetes mellitus (GDM) treatment trial or concurrent non-GDM cohort. Maternal serum insulin concentrations and cardiovascular markers VCAM-1, VEGF, CD40L, GDF-15, and ST-2 were measured, and insulinogenic index (IGI, pancreatic β-cell function) and 1/ homeostatic model assessment (insulin resistance) were calculated. Biomarkers were compared by presence of HDP (gestational hypertension or preeclampsia) during pregnancy. Multivariable linear regression estimated the association of HDP with biomarkers, adjusting for GDM, baseline body mass index (BMI), and years since pregnancy.
Of 642 patients, 66 (10%) had HDP: 42 with gestational hypertension and 24 with preeclampsia. Patients with HDP had higher baseline and follow-up BMI, higher baseline blood pressure, and more chronic hypertension at follow-up. HDP was not associated with metabolic or cardiovascular biomarkers at follow-up. However, when HDP type was evaluated, patients with preeclampsia had lower GDF-15 levels (oxidative stress/cardiac ischemia), compared with patients without HDP (adjusted mean difference: -0.24, 95% confidence interval: -0.44, -0.03). There were no differences between gestational hypertension and no HDP.
In this cohort, metabolic and cardiovascular biomarkers 5 to 10 years after pregnancies did not differ by HDP. Patients with preeclampsia may have less oxidative stress/cardiac ischemia postpartum; however, this may have been observed due to chance alone given multiple comparisons. Longitudinal studies are needed to define the impact of HDP during pregnancy and interventions postpartum.
· Hypertensive disorders of pregnancy were not associated with metabolic dysfunction.. · Cardiovascular dysfunction was not consistently seen after pregnancy hypertension.. · Longitudinal studies with postpartum interventions after preeclampsia are needed..
本研究旨在衡量妊娠高血压疾病(HDP)与孕产妇长期代谢及心血管生物标志物之间的关联。
对在轻度妊娠期糖尿病(GDM)治疗试验或同期非GDM队列入组5至10年后完成葡萄糖耐量试验的患者进行随访研究。测量孕产妇血清胰岛素浓度以及心血管标志物血管细胞黏附分子-1(VCAM-1)、血管内皮生长因子(VEGF)、肿瘤坏死因子受体超家族成员40配体(CD40L)、生长分化因子15(GDF-15)和基质细胞衍生因子-2(ST-2),并计算胰岛素生成指数(IGI,胰腺β细胞功能)和1/稳态模型评估(胰岛素抵抗)。根据孕期是否存在HDP(妊娠期高血压或子痫前期)对生物标志物进行比较。多变量线性回归估计HDP与生物标志物之间的关联,并对GDM、基线体重指数(BMI)和产后年限进行校正。
642例患者中,66例(10%)患有HDP:42例为妊娠期高血压,24例为子痫前期。患有HDP的患者基线和随访时的BMI更高,基线血压更高,随访时慢性高血压更多。随访时HDP与代谢或心血管生物标志物无关。然而,在评估HDP类型时,子痫前期患者的GDF-15水平(氧化应激/心肌缺血)低于无HDP的患者(校正平均差异:-0.24,95%置信区间:-0.44,-0.03)。妊娠期高血压与无HDP之间无差异。
在该队列中,妊娠后5至10年的代谢和心血管生物标志物在HDP患者与非HDP患者之间并无差异。子痫前期患者产后可能具有较低的氧化应激/心肌缺血水平;然而,鉴于进行了多次比较,这可能仅是偶然观察到的结果。需要开展纵向研究以明确孕期HDP的影响及产后干预措施。
· 妊娠高血压疾病与代谢功能障碍无关。· 妊娠高血压后并非始终出现心血管功能障碍。· 需要对子痫前期后进行产后干预的纵向研究。